Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: October 3, 2017, 5-9PM
Minutes prepared by: Nina Bandali and Dave Hoang
Location: Elmer Andersen Building, Room 2340, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., Ph.D., Al Heaton, RPh., Kyle Lehenbauer, M.D., Stacey Ness, Pharm.D., Michael Sprehe, M.D., Stuart Williams, J.D., RPh
- Members absent: Monica Brands, RPh., Kathryn Lombardo, M.D., Eric Meininger, M.D., James Phillips, M.D., Kelly Ruby, Pharm.D.
- DHS staff present: Chad Hope, Pharm.D., Dave Hoang, Pharm.D., MBA, Mary Beth Reinke, Pharm.D., MSA.
- Others in attendance: Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair

No updates

Approval of Minutes

Minutes from the August 2017 meeting were reviewed and approved.

Review of List of Excluded Drugs

- The Drug Formulary Committee established under section 256B.0625, subdivision 13, shall establish a list of drug products that are to be excluded from substitution. The committee recommended by a unanimous vote not to make any changes.

Class Review: New Specialty Drugs for Continued PA

- The committee discussed two new pangenotypic Hepatitis C agents (Mavyret and Vosevi) and recommended to the department by a unanimous vote that both Mavyret and Vosevi remain on PA based on whether the patient is treatment naïve or treatment experienced.
New Specialty Drugs for Continued PA

- The committee discussed Zejula and recommended to the department by a unanimous vote that Zejula remain on PA with a modification on the verbiage so that denial criteria is converted to approval criteria.
- The committee discussed Alunbrig and recommended to the department by a unanimous vote that Alunbrig remain on PA with a modification on the verbiage so that denial criteria is converted to approval criteria.
- The committee discussed Rydapt and recommended to the department by a unanimous vote that Rydapt remain on PA.
- The committee discussed Imfinzi and recommended to the department by a unanimous vote that Imfinzi remain on PA.
- The committee discussed Tymlos and recommended to the department by a unanimous vote that Tymlos remain on PA.
- The committee discussed Brineura and recommended to the department by a unanimous vote that Brineura remain on PA.
- The committee discussed Xadago and recommended to the department by a unanimous vote that Xadago remain on PA.
- The committee discussed Haegarda and recommended to the department by a unanimous vote that Haegarda remain on PA.
- The committee discussed Ingrezza and recommended to the department by a unanimous vote that Ingrezza remain on PA with a modification on the verbiage so that denial criteria is converted to approval criteria.
- The committee discussed Kevzara and recommended to the department by a unanimous vote that Kevzara remain on PA.
- The committee discussed Tremfya and recommended to the department that it be brought back for review.

Adjournment

- Public Member, Stuart Williams, has been reappointed for another 3-year term.
- The meeting was adjourned at 7:55 PM Central Time.